Lupin launches generic Levothyroxine Sodium tablets

Lupin's Levothyroxine Sodium tablet is the generic version of AbbVie Inc's Synthroid tablets, it added.

New Delhi: Drug firm Lupin Friday said it has launched generic Levothyroxine Sodium tablets in the US market. The company has launched Levothyroxine Sodium tablets USP after receiving approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a BSE filing.

The company's product is the generic version of AbbVie Inc's Synthroid tablets, it added.

Also Read: Lupin gets USFDA nod to Methylprednisolone tablets to treat inflammation

The tablets are indicated as replacement or supplemental therapy for hypothyroidismand as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer, Lupin said.

As per IQVIA MAT January 2019 data, Levothyroxine Sodium tablets in the strengths of 25 meg, 50 meg, 75 meg, 88 meg, 100 meg, 112 meg, 125 meg, 137 meg, 150 meg, 175 meg, 200 meg, and 300 meg had an annual sales of around USD 2.5 billion in the US market, it added.

Headquartered in Mumbai, Lupin develops and delivers a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds a position in the Anti-TB segment.

Also Read: Lupin, Natco receives USFDA nod for Imatinib Mesylate tablets